Log in

Aurinia Pharmaceuticals Stock Forecast, Price & News

+0.60 (+4.01 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $15.55
50-Day Range
MA: $14.27
52-Week Range
Now: $15.55
Volume1.22 million shs
Average Volume1.50 million shs
Market Capitalization$1.96 billion
P/E RatioN/A
Dividend YieldN/A
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Read More
Aurinia Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AUPH



Sales & Book Value

Annual Sales$320,000.00
Book Value$2.45 per share


Net Income$-123,850,000.00
Net Margins-48,648.11%


Market Cap$1.96 billion
Next Earnings Date11/12/2020 (Estimated)
+0.60 (+4.01 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AUPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

How has Aurinia Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AUPH shares have increased by 10.3% and is now trading at $15.55.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Aurinia Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aurinia Pharmaceuticals

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Aurinia Pharmaceuticals

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its earnings results on Tuesday, August, 11th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.03. The biotechnology company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 41.60% and a negative net margin of 48,648.11%.
View Aurinia Pharmaceuticals' earnings history

What price target have analysts set for AUPH?

8 brokers have issued 1 year price objectives for Aurinia Pharmaceuticals' stock. Their forecasts range from $20.00 to $34.00. On average, they expect Aurinia Pharmaceuticals' share price to reach $25.43 in the next year. This suggests a possible upside of 63.5% from the stock's current price.
View analysts' price targets for Aurinia Pharmaceuticals

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Array Biopharma (ARRY), Amarin (AMRN) and Alibaba Group (BABA).

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the following people:
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Richard M. Glickman, Advisor (Age 61)
  • Dr. Neil Solomons M.D., Chief Medical Officer

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (4.72%), Point72 Asset Management L.P. (3.05%), Avidity Partners Management LP (1.96%), Orbimed Advisors LLC (0.95%), Artal Group S.A. (0.71%) and Assenagon Asset Management S.A. (0.79%).

Which institutional investors are selling Aurinia Pharmaceuticals stock?

AUPH stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Goldman Sachs Group Inc., Atom Investors LP, Orbimed Advisors LLC, Assenagon Asset Management S.A., Hudson Bay Capital Management LP, and UBS Group AG.

Which institutional investors are buying Aurinia Pharmaceuticals stock?

AUPH stock was purchased by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, TD Asset Management Inc., Man Group plc, Bank of Montreal Can, Ikarian Capital LLC, Tobam, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, and Alps Advisors Inc..

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $15.55.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of $1.96 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.